Skip to content
conflictLOW2026-05-06 02:33 UTC

Neurocrine reaffirms $2.7B-$2.8B INGREZZA outlook while acquisition of Soleno remains on track for Q2 close

ORIGINAL SOURCE →via Seeking Alpha
ADVERTISEMENT
⚡ STAY AHEAD

Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.

GET THE SUNDAY BRIEFING →

RELATED · conflict